The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Open accessAbstract
BACKGROUND: Recent Mycobacterium tuberculosis infection confers a predisposition to the development of tuberculosis disease, the leading killer among global infectious diseases. H4:IC31, a candidate subunit vaccine, has shown protection against tuberculosis disease in preclinical models, and observational studies have indicated that primary bacille Calmette-Guérin (BCG) vaccination may offer partial protection against infection. METHODS: In this phase 2 trial, we randomly assigned 990 adolescents in a high-risk setting who had undergone neonatal BCG vaccination to receive the H4:IC31 vaccine, BCG revaccination, or placebo. All the participants had negative results on testing for M. tuberculosis infection on the QuantiFERON-TB Gold In-tube assay (QFT) and for the human immunodeficiency virus. The primary outcomes were safety and acquisition of M. tuberculosis infection, as defined by initial conversion on QFT that was performed every 6 months during a 2-year period. Secondary outcomes were immunogenicity and sustained QFT conversion to a positive test without reversion to negative status at 3 months and 6 months after conversion. Estimates of vaccine efficacy are based on hazard ratios from Cox regression models and compare each vaccine with placebo. RESULTS: Both the BCG and H4:IC31 vaccines were immunogenic. QFT conversion occurred in 44 of 308 participants (14.3%) in the H4:IC31 group and in 41 of 312 participants (13.1%) in the BCG group, as compared with 49 of 310 participants (15.8%) in the placebo group; the rate of sustained conversion was 8.1% in the H4:IC31 group and 6.7% in the BCG group, as compared with 11.6% in the placebo group. Neither the H4:IC31 vaccine nor the BCG vaccine prevented initial QFT conversion, with efficacy point estimates of 9.4% (P=0.63) and 20.1% (P=0.29), respectively. However, the BCG vaccine reduced the rate of sustained QFT conversion, with an efficacy of 45.4% (P=0.03); the efficacy of the H4:IC31 vaccine was 30.5% (P=0.16). There were no clinically significant between-group differences in the rates of serious adverse events, although mild-to-moderate injection-site reactions were more common with BCG revaccination. CONCLUSIONS: In this trial, the rate of sustained QFT conversion, which may reflect sustained M. tuberculosis infection, was reduced by vaccination in a high-transmission setting. This finding may inform clinical development of new vaccine candidates. (Funded by Aeras and others; C-040-404 ClinicalTrials.gov number, NCT02075203 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Self-citationProtection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials
Mangtani, P., Abubakar, I., Ariti, C., Beynon, R., Pimpin, L., Fine, P. E. M., Rodrigues, L. C., Smith, P. G., Lipman, M., Whiting, P. F., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit790 · Cited by 995
Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection
Pai, M., Denkinger, C. M., Kik, S. V., Rangaka, M. X., Zwerling, A., Oxlade, O., Metcalfe, J. Z., Cattamanchi, A., Dowdy, D. W., Dheda, K., et al. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-13 · Cited by 886
Roy, A., Eisenhut, M., Harris, R. J., Rodrigues, L. C., Sridhar, S., Habermann, S., Snell, L., Mangtani, P., Adetifa, I., Lalvani, A., et al. (2014) · BMJ · doi:10.1136/bmj.g4643 · Cited by 588
Lin, P. L., Ford, C. B., Coleman, M. T., Myers, A. J., Gawande, R., Ioerger, T., Sacchettini, J., Fortune, S. M., & Flynn, J. L. (2014) · Nature Medicine · doi:10.1038/nm.3412 · Cited by 533
Abubakar, I., Pimpin, L., Ariti, C., Beynon, R., Mangtani, P., Sterne, J., Fine, P., Smith, P., Lipman, M., Elliman, D., et al. (2013) · Health Technol Assess · doi:10.3310/hta17370 · Cited by 498
Cadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.69 · Cited by 484
Soysal, A., Millington, K. A., Bakir, M., Dosanjh, D., Aslan, Y., Deeks, J. J., Efe, S., Staveley, I., Ewer, K., & Lalvani, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67534-4 · Cited by 291
Rodrigues, L. C., Pereira, S. M., Cunha, S. S., Genser, B., Ichihara, M. Y., de Brito, S. C., Hijjar, M. A., Cruz, A. A., Sant'Anna, C., Bierrenbach, A. L., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67145-0 · Cited by 286
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Non-specific effects of BCG vaccine on viral infections
Moorlag, S. J. C. F. M., Arts, R. J. W., van Crevel, R., & Netea, M. G. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.020 · Cited by 479
BCG-induced trained immunity: can it offer protection against COVID-19?
O’Neill, L. A. J., & Netea, M. G. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0337-y · Cited by 498
Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection
Netea, M. G., Giamarellos-Bourboulis, E. J., Domínguez-Andrés, J., Curtis, N., van Crevel, R., van de Veerdonk, F. L., & Bonten, M. (2020) · Cell · doi:10.1016/j.cell.2020.04.042 · Cited by 468
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C., Chaisson, R., Chin, D. P., Churchyard, G., Cox, H., Ditiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 361
Metadata
- Authors
- Nemes, E., Geldenhuys, H., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., Mulenga, H., Hanekom, W. A., Self, S. G., Bekker, L.-G., Ryall, R., Gurunathan, S., DiazGranados, C. A., Andersen, P., Kromann, I., Evans, T., Ellis, R. D., Landry, B., Hokey, D. A., Hopkins, R., Ginsberg, A. M., Scriba, T. J., & Hatherill, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-07-12
- Volume
- 379
- Issue
- 2
- Pages
- 138-149
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2872754763
- Cited by
- 652
- References
- 32
- FWCI
- 56.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. https://app.cochat.ai/papers/10.1056/nejmoa1714021
- The paper
- Nemes, E., Geldenhuys, H., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., Mulenga, H., Hanekom, W. A., Self, S. G., Bekker, L.-G., Ryall, R., Gurunathan, S., DiazGranados, C. A., Andersen, P., Kromann, I., . . . Hatherill, M. (2018). Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1714021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.